Chest
Original ResearchCOPDStatins in COPD: A Systematic Review
Section snippets
Materials and Methods
We decided a priori to examine the published evidence of statin therapy in patients with COPD. Searches were conducted on Medline (inception to December 2008), Excerpta Medica Database (inception to December 2008), PapersFirst (inception to December 2008), and the Cochrane collaboration and Cochrane Register of controlled trials for relevant trials. The following key terms were used: “statins”; “fluvastatin”; “simvastatin”; “atorvastatin”; “rosuvastatin”; “lovastatin”; “pravastatin”;
Results
We identified nine studies15, 16, 17, 18, 19, 20, 21, 22, 23 that described the use of statins and their potential clinical effects in patients with COPD (Fig 1). Of these evaluable studies, four were retrospective cohort studies, one was a nested case-control study of a retrospective cohort, one was a combination retrospective cohort study, two were case-control studies, one was a randomized controlled trial (RCT), and two were population-based analyses (Table 1). The end points that were
Discussion
Statins not only have a proven role in treating CV patients, primarily through their cholesterol-lowering ability, but also possess antiinflammatory and immunomodulatory pleiotropic effects postulated to be beneficial to patients with COPD. We identified nine studies that evaluated the effect of statins on various outcomes in COPD. Eight of the studies were retrospective cohorts, case-control studies, or epidemiologic analyses. Only one interventional study specifically designed to address the
Acknowledgments
Author contributions: Dr. Janda had full access to all the data in the study and takes full responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Drs. Janda and Swiston. Literature search: Drs. Janda and Park. Acquisition of data: Dr. Janda. Analysis and interpretation of data: Drs. Janda, Etminan, and Swiston. Drafting of the manuscript: Drs. Janda and Swiston. Comments and final review: Drs. Fitzgerald and Swiston.
Financial/nonfinancial
References (0)
Cited by (116)
Atherosclerosis: Conventional intake of cardiovascular drugs versus delivery using nanotechnology – A new chance for causative therapy?
2021, Journal of Controlled ReleaseLncRNA SNHG5 regulates cell apoptosis and inflammation by miR-132/PTEN axis in COPD
2020, Biomedicine and PharmacotherapyAssociation of lung function and chronic obstructive pulmonary disease with American Heart Association's Life's Simple 7 cardiovascular health metrics
2017, Respiratory MedicineCitation Excerpt :While our study did not look at statin use specifically, long-term statin use (>2 years) were associated with a 39% decreased risk of death in COPD patients [41]. A systematic review had found nine studies that showed a benefit from statin therapy for various outcomes, including COPD exacerbation, the number of and time to COPD-related intubations, pulmonary function, exercise capacity, mortality from COPD and all-cause mortality [42]. As a composite score, LS7 had indicated the effect of LS7 metrics as a whole in association with COPD and lung function.
Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: A sub-analysis of GISSI-HF trial
2017, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :By contrast, the Rotterdam study found that statin use was associated with a beneficial effect on all-cause mortality in COPD, depending on the level of systemic inflammation [14]. Those results are in line with several positive studies on the beneficial effect of statins in COPD [15]. However, a recent prospective, randomized clinical trial, failed to show any beneficial effect of simvastatin, at the daily dose of 40 mg, on exacerbations in patients with COPD and high risk of exacerbations [16].
Pharmacological treatment optimization for stable chronic obstructive pulmonary disease. Proposals from the Société de Pneumologie de Langue Française
2016, Revue des Maladies Respiratoires
Funding/Support: Dr. FitzGerald is a Michael Smith Foundation for Health Research Distinguished Scholar and a Canadian Institutes of Health Research/British Columbia Lung Scientist recipient, funded in part by the National Sanitarium Association. Dr. Swiston is a recipient of an In it for Life Scientist award from the Vancouver Coastal Health Research Institute and the Vancouver General Hospital Foundation. Work was performed at the University of British Columbia.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml).